In Situ Hybridization Market Trends

Growth Drivers

Presence of High-Quality Molecular Tests – In situ hybridization (ISH), a very potent molecular technique, that is used to diagnose certain chromosomal abnormalities by assessing the presence or absence of fluorescence-labeled signals in interphase or metaphase nuclei or chromosomes.
Growing Elderly Population- The elderly population is more prone to age-related disorders such as cancer and other neurodegenerative diseases which is expected to drive the demand for in situ hybridization as this technology is widely used to study cancer, infectious diseases, and developmental biology, and can be used to detect cryptic chromosomal abnormalities and small aberrant clones.

According to the World Health Organization (WHO), the number of individuals in the world who are 60 or older will increase to 2.1 billion by 2050.

Spiking Prevalence of Infectious Diseases- In situ hybridization (ISH) is a potent method for detecting specific RNAs and was created with the technology of molecular genetics to identify infectious pathogens.
Increasing Trend of Minimally Invasive Procedures- The in situ hybridization (FISH) assay is a non-invasive method used to diagnose and track urothelial carcinoma (UC) in the upper urinary tract (UUT) and the test also looks for chromosomal alterations.
Rising Advancements in Digital Pathology- Digital pathology is a branch of pathology that, will be used as a tool for FISH imaging in both clinical and research settings rather than live microscopy slides in the future.

Challenges

Exorbitant Cost of In Situ Hybridization Assays- In situ hybridization is expensive owing to the use of the high cost of the specialized reagents, as well as the high cost of probes. Besides this, the technology is labor-intensive and consequently expensive for labs to utilize as it requires trained medical professionals and expertise.
Lack of Skilled Professionals to Carryout In Situ Hybridization Diagnosis
Growing Preference for Alternative Molecular Technologies Including Polymerase Chain Reaction (PCR)

In Situ Hybridization Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	~12%
Base Year Market Size (2023)	~ USD 2 Billion
Forecast Year Market Size (2036)	~ USD 4 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

The rising incidence of cancer across the globe and the growing technological advancements in In-vitro diagnostics (IVD) are the major factors driving the growth of the market.

The market size of In Situ Hybridization is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 â€“ 2036.

The major players in the market are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, and others.

The fluorescent In situ hybridization (FISH) segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

In Situ Hybridization Market Trends